Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gastrointestinal cancers – still many questions to be resolved

Gastrointestinal cancers – still many questions to be resolved editorial memo (2011) Vol. 4: 61 DOI 10.1007/s12254-011-0269-0 Printed in Austria © Springer-Verlag 2011 Gastrointestinal cancers – still many questions to be resolved E. Wöll Ewald Wöll St. Vinzenz Hospital Zams, Zams, Austria Received 8 April 2011; accepted 19 April 2011 Treatment of gastrointestinal neoplasias has changed sub- inoperable gastric cancer HER 2 positivity serves as a predic- stantially during the last decade. Nihilism and poor response tive marker for trastuzumab in combination with chemother- rates have been replaced by aggressive treatment strategies apy. In hepatocellular carcinoma and cholangiocellular and even curative approaches in metastatic colorectal cancer carcinoma treatment in inoperable disease could be improved for example. A major achievement is the multidisciplinary substantially. treatment – lead by tumour boards – enabling optimal treat- Optimal treatment however includes aggressive side ef- ment sequences and utilization of diff erent treatment mo- fect management. Th erefore one review addresses special as- dalities. Increase in response rates and prolongation of pects of side eff ect management in gastrointestinal cancers survival is also achieved by the use of novel cytostatic drugs [10]. and implementation of so called “targeted therapies” . I am very grateful to all authors for their excellent re- In spite http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Gastrointestinal cancers – still many questions to be resolved

Download PDF
1 page

Gastrointestinal cancers – still many questions to be resolved

Abstract

editorial memo (2011) Vol. 4: 61 DOI 10.1007/s12254-011-0269-0 Printed in Austria © Springer-Verlag 2011 Gastrointestinal cancers – still many questions to be resolved E. Wöll Ewald Wöll St. Vinzenz Hospital Zams, Zams, Austria Received 8 April 2011; accepted 19 April 2011 Treatment of gastrointestinal neoplasias has changed sub- inoperable gastric cancer HER 2 positivity serves as a predic- stantially during the last decade. Nihilism and poor response tive marker for...
Loading next page...
 
/lp/springer-journals/gastrointestinal-cancers-still-many-questions-to-be-resolved-7JOprj0KJD
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0269-0
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2011) Vol. 4: 61 DOI 10.1007/s12254-011-0269-0 Printed in Austria © Springer-Verlag 2011 Gastrointestinal cancers – still many questions to be resolved E. Wöll Ewald Wöll St. Vinzenz Hospital Zams, Zams, Austria Received 8 April 2011; accepted 19 April 2011 Treatment of gastrointestinal neoplasias has changed sub- inoperable gastric cancer HER 2 positivity serves as a predic- stantially during the last decade. Nihilism and poor response tive marker for trastuzumab in combination with chemother- rates have been replaced by aggressive treatment strategies apy. In hepatocellular carcinoma and cholangiocellular and even curative approaches in metastatic colorectal cancer carcinoma treatment in inoperable disease could be improved for example. A major achievement is the multidisciplinary substantially. treatment – lead by tumour boards – enabling optimal treat- Optimal treatment however includes aggressive side ef- ment sequences and utilization of diff erent treatment mo- fect management. Th erefore one review addresses special as- dalities. Increase in response rates and prolongation of pects of side eff ect management in gastrointestinal cancers survival is also achieved by the use of novel cytostatic drugs [10]. and implementation of so called “targeted therapies” . I am very grateful to all authors for their excellent re- In spite

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • Adjuvant therapy in colon carcinoma stages II and III
    Thaler, J; Resch, G
  • (Neo-) Adjuvant Radio Chemotherapy in stage II/III Rectal cancer
    Hoffmann, W; Lordick, F; Becker-Schiebe, M
  • Recent developments and future persepectives in systemic treatment of metastatic colorectal cancer
    Hacker, UT; Coutelle, O; Hallek, M
  • Bowel first? simultaneous resection? Liver First? Treatment options in patients with colorectal cancer and resectable synchronous liver metastases
    Zitt, M
  • Can radiofrequency ablation replace liver resection?
    Bale, R; Widmann, G
  • Contribution of PET-CT in the management of GI-cancer
    Gabriel, M
  • Current treatment strategies of esophageal carcinoma
    Ruhstaller, T; Stahl, M
  • Gastric Cancer
    Lordick, F; Schumacher, G; Becker-Schiebe, M
  • Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas
    Köberle, D; Samaras, P
  • Side-effect management during. treatment of GI-cancers
    Becker-Schiebe, M; Lordick, F; Hoffmann, W